Many studies have determined the correlation between the Apolipoprotein E (APO E) gene polymorphisms and diabetic nephropathy, but their results are inconclusive.
Background
Diabetic nephropathy (DN) is the leading cause of chronic renal disease and a major cause of cardiovascular mortality. Diabetic nephropathy is associated with cardiovascular disease and increases mortality of diabetic patients [1] . Diabetic nephropathy has been categorized into 2 stages: microalbuminuria and macroalbuminuria. Several factors are involved in the pathophysiology of DN, including metabolic and hemodynamic alterations, oxidative stress, activation of the renin-angiotensin system, immunoregulatory cytokines [2, 3] and genetic factors. The 2 main risk factors for diabetic nephropathy are hyperglycemia and arterial hypertension, but the genetic susceptibility in type 1 and type 2 diabetes is of great importance [4] . Previous studies have shown that type 2 diabetes (T2D) is a metabolic disorder characterized by hyperglycemia, developing insulin resistance, b-cell dysfunction, and impaired insulin secretion. As the incidence of type 2 diabetes continues to rise world-wide, the personal and social burdens associated with this complication are becoming increasingly serious. A familial study has provided compelling evidence that genetic factors contribute to DN susceptibility in T2D [5] as have studies aimed at identifying the causal genes responsible for its development.
The Apolipoprotein E (APO E) gene, located on chromosome 19q13.2, has 3 common alleles -2, 3, and 4 -coding for the 3 main isoforms of the Apo E protein: e2 (Arg®Cys), e3 (parent isoform), and e4 (Arg®Cys). There are 6 common Apo E polymorphisms: Apo e3/3, Apo e4/4, Apo e2/2, Apo e3/2, Apo e4/2, and Apo e4/3 [6] .
Many studies have investigated gene APO E polymorphism effects on susceptibility to type 2 diabetic nephropathy, and we have summarized the findings of those individual studies in the Appendix 1. Meta-analysis is a powerful method for quantitatively summarizing results from different studies. One of its advantages is to increase the sample size, which may reduce the probability that random error will result in a false-positive or false-negative association. Therefore, we performed a meta-analysis to quantitatively assess the association of APO E gene polymorphisms with DN.
Material and Methods

Literature search strategy
The Medline, PubMed, Embase, and Web of Science were searched (the last search was updated on June, 10, 2014 using the search terms: 'Diabetic Nephropathy'' or ''DN'', ''polymorphism'', ''APO E'' or ''Apolipoprotein E''. All searched studies were retrieved and their bibliographies were checked for other relevant publications. Review articles and bibliographies of other relevant identified studies were hand-searched in addition to eligible studies. Only published studies with full-text articles were included. When more than one of the same patient populations was included in several publications, only the one with the sample size largest or the most complete study was used in this meta-analysis. A flow diagram of the study selection process is shown in Figure 1 .
Inclusion and exclusion criteria
The inclusion and exclusion criteria were determined by discussion. The inclusion criteria were: (1) the study aimed to examine the association between APO E polymorphisms and susceptibility to DN; (2) the design type of the study was a case-control study; (3) the study used diabetic patients without nephropathy or healthy subjects as controls; (4) the study provided the number of DN cases or controls and the frequency of APO E genotypes.
The exclusion criteria were: (1) the study did not fit the diagnosis criteria; (2) the study was conducted on animals; (3) the study was not a case-control study; (4) the study reported useless data; (5) the study focused on type 1 diabetic subjects.
Data extraction
All of the data were extracted independently by 2 reviewers (Yijin Lin and Jinlin Pan) according to the pre-specified selection criteria. Disagreement was resolved by discussion. The following data were extracted: control type, diabetic duration, study design, first author's name, publication year, and number of cases with normoalbuminuria, microalbuminuria, and macroalbuminuria, and number of healthy controls.
Statistical analysis
Allele frequencies at the APO E single-nucleotide polymorphisms (SNPs) from the studies were determined by the allele counting method. Statistical analysis was conducted using Stata 11.0 (StataCorp, College Station, TX) and a P-value £0.05 was considered to be statistically significant. Dichotomous data are presented as the odds ratio (OR) with a 95% confidence interval (CI). Statistical heterogeneity was measured using the Q-statistic (P£0.10 was considered to be representative of statistically significant heterogeneity). We also quantified the effect of heterogeneity using the I 2 statistic, which measures the degree of inconsistency in the studies by calculating what percentage of the total variation across studies is due to heterogeneity rather than by chance. A fixed-effects model was used when there was no heterogeneity of the results of the trials; otherwise, the random effects model was used. For dichotomous outcomes, patients with incomplete or missing data and small-sample studies were included in the sensitivity analyses by counting them as treatment failures. To establish the effect of clinical heterogeneity between studies on the conclusions of meta-analyses, subgroup analysis was conducted on the basis of race. Several methods were used to assess the potential for publication bias. Visual inspection of asymmetry in funnel plots was conducted. Begg's rank correlation method and Egger's weighted regression method were also used to statistically assess the publication bias (P£0.05 was considered to be representative of statistically significant publication bias).
Results
Characteristics of studies
This meta-analysis included 16 relevant studies of APO E SNPs, with 1754 cases and 3912 controls. The characteristics of each study are presented in the Appendix 1.
Quantitative data synthesis
The aim of this study was to use the meta-analysis method to quantitatively summarize the results from the selected individual studies. In comparing DN cases versus diabetic patients without nephropathy, our was aim to evaluate the relationship between APO E polymorphisms on the progress of diabetic patients. The carriers of the APO e2 allele were more likely to have DN than the over-all group, the East Asia group, and the Japan group, but not in the 3 other subgroups (e2 allele vs. Figure 2) To understand the influence of diabetes duration on the development of diabetes, we divided the included studies into 2 parts by duration of diabetes, comparing the group with >10 years duration versus the group with duration <10 years. As Table 1 and Figure 3 show, the carriers of the APO e2 allele were associated with progression of DN in the duration > 10 years group, but not in the duration <10 years group (e2 allele vs. (Figure 4 ).
To further verify the association of development of DN and APO E polymorphisms, we quantitatively summarized the results of microalbuminuria versus normoalbuminuria and macroalbuminuria versus normoalbuminuria. The meta-analysis results of these 2 comparisons supported the results above -APO e2 allele polymorphism was associated with the progression of DN (Table 2 ).
There were 3 prospective studies among the papers included in this meta-analysis, and the pooled results verified the conclusion of the case-control studies -the APO e2 allele polymorphism was a risk factor in the development of DN (Progression vs. Non-progression: e2 allele vs. e3 allele: pooled RR=1.636, 95% CI=1.093-2.449, P=0.017; e2 group vs. e3 group pooled RR=1.711, 95% CI=1.124-2.606, P=0.012). We found a significant difference in comparison of 'e2 allele vs. e3 allele' group among 'Progression vs. Non-progression', but there were no other result supporting this conclusion (Table 2 ).
Heterogeneity
The heterogeneity was calculated among all studies using the Q-statistic (Q>0.05) and the I 2 statistic (I=0.0%). Heterogeneity was found in some groups, and the random-effects model was used.
Sensitivity analysis
A single study was deleted each time to investigate the influence of the individual dataset on the pooled ORs. The corresponding pooled ORs were not materially altered (data not shown), indicating that our results are statistically robust.
Publication bias
Begg's funnel plot and Egger's test were performed to assess the publication bias of the literature. We found no asymmetry of the funnel plot, suggesting that there was no publication bias in our meta-analysis. 
Discussion
Diabetic nephropathy (DN) is a major contributor to the high mortality of patients with DM [23] . Several acquired risk factors, such as abnormal lipoprotein metabolism, hypertension, and hyperglycemia, have been identified for the development of DN [24] . Genetic susceptibility is thought to contribute to the pathogenesis of this complication. Studies of patients with type 2 DM have shown either that the e2 allele is a risk factor for DN or no association between Apo E polymorphism and DN e2 carrier (e2/2, e2/3 genotypes), e3 group (e3/3 genotype) and e4 group (e3/4, e4/4 genotype). The progressors on DN were defined as the subjects who shifted to a higher stage of DN from that at the baseline. 
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of DN, and e4 was a protective factor [9] . Conversely, there are conflicting results regarding the impact of allele e2 and e4 on the development of DN. The APO e2 allele did not appear to be associated with increased risk of renal impairment in Chinese type 2 diabetic patients [21] and a study indicated that the e4 allele of the Apo E polymorphism is one of the prognostic risk factors involved in the development of DN with type 2 diabetes mellitus [7] .
The results of this study suggest that APO e2 allele is more likely to increase the risk of DN, while APO e4 allele is not associated with the DN development and susceptibility in an East Asia population. Specifically, the OR value of most included studies (3/15) were larger than 1 when the e2 allele and APO e3 was compared (Figure 2 ). This finding indicates that the negative results of those studies might be due to inadequate sample size. In addition to the sample size, another reason for this inconsistency is the duration of diabetes in the DN and non-DN groups. This meta-analysis shows that, in most individual studies in patients with diabetes duration >10 years group, there is a significant correlation between DN and APO e2, but none of the studies had positive results in subgroups of patients with diabetes duration <10 years ( Figure 3) . The defective ability of the APO e2 isoform to bind to Apo E receptors may increase the risk of DN.
There are some limitations to this study. Firstly, because only published studies were included in the meta-analysis, publication bias may have occurred, even though it was not found by statistical tests. Secondly, a meta-analysis essentially retains the methodological deficiencies of the included studies. Finally, this metaanalysis is based on unadjusted estimates, while a more precise analysis could be performed if individual data were available.
Conclusions
In conclusion, in spite of several limitations mentioned above, this meta-analysis suggests that APO e2 mutation increased the development of DN, especially in East Asian populations.
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